论文部分内容阅读
目的探讨炎症性肠炎病患者应用益生菌联合美沙拉嗪的治疗效果。方法 76例炎症性肠炎病患者,随机分为观察组和对照组,各38例。对照组口服美沙拉嗪,观察组在对照组基础上服用益生菌。8周后对两组患者的不良反应和临床疗效作出比较。结果观察组患者的结肠镜检查总有效率与对照组相比差异具有统计学意义(P<0.05);观察组患者的腹痛腹泻以及皮疹等不良反应明显好于对照组,差异有统计学意义(P<0.05)。结论益生菌联合美沙拉嗪对炎症性肠炎病患者的治疗效果好,患者满意度高,可应用于临床治疗。
Objective To investigate the therapeutic effect of probiotics combined with mesalazine in patients with inflammatory bowel disease. Methods 76 cases of inflammatory bowel disease patients were randomly divided into observation group and control group, 38 cases each. The control group was given mesalazine orally, and the observation group took probiotics on the basis of the control group. Eight weeks later, the adverse reactions and clinical outcomes of the two groups were compared. Results The total effective rate of colonoscopy in observation group was statistically different from that in control group (P <0.05). Adverse reactions such as abdominal pain and diarrhea and skin rashes in observation group were significantly better than those in control group (P <0.05) P <0.05). Conclusions Probiotics combined with mesalazine have a good therapeutic effect on patients with inflammatory bowel disease and patients with high satisfaction can be applied to clinical treatment.